Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Shepshelovich

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
JAMA Internal Medicine|September 28, 2020
Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety CommunicationsNoam Tau, Daniel Shepshelovich
Oncotarget|August 21, 2018
Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?Daniel Shepshelovich, Eitan Amir
JAMA Internal Medicine|December 20, 2021
Emergency Use Authorizations of COVID-19-Related Medical ProductsItay Moshkovits, Daniel Shepshelovich
Human Vaccines & Immunotherapeutics|December 3, 2020
Vaccine safety - is the SARS-CoV-2 vaccine any different?Noam Tau, Dafna Yahav, Daniel Shepshelovich
Harefuah|September 9, 2005
[Accelerated atherosclerosis in rheumatoid arthritis]Daniel Shepshelovich, Yaniv Sherer, Yehuda Shoenfeld
The Israel Medical Association Journal : IMAJ|November 27, 2022
Predicting Which Patients Are at Risk for Clinical Deterioration in COVID-19: A Review of the Current Models in UseMichael Shapiro, Yarden Yavne, Daniel Shepshelovich
Leukemia & Lymphoma|May 26, 2020
Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administrationIrina Amitai, Pia Raanani, Daniel Shepshelovich
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 28, 2020
Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant BacteriaDafna Yahav, Noam Tau, Daniel Shepshelovich
Annals of Internal Medicine|July 28, 2020
Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort StudyNoam Tau, Dafna Yahav, Daniel Shepshelovich
Infectious Diseases and Therapy|February 17, 2021
Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the GapDafna Yahav, Daniel Shepshelovich, Noam Tau
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
JAMA Internal Medicine|September 28, 2020
Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety CommunicationsNoam Tau, Daniel Shepshelovich
Oncotarget|August 21, 2018
Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?Daniel Shepshelovich, Eitan Amir
JAMA Internal Medicine|December 20, 2021
Emergency Use Authorizations of COVID-19-Related Medical ProductsItay Moshkovits, Daniel Shepshelovich
Human Vaccines & Immunotherapeutics|December 3, 2020
Vaccine safety - is the SARS-CoV-2 vaccine any different?Noam Tau, Dafna Yahav, Daniel Shepshelovich
Harefuah|September 9, 2005
[Accelerated atherosclerosis in rheumatoid arthritis]Daniel Shepshelovich, Yaniv Sherer, Yehuda Shoenfeld
The Israel Medical Association Journal : IMAJ|November 27, 2022
Predicting Which Patients Are at Risk for Clinical Deterioration in COVID-19: A Review of the Current Models in UseMichael Shapiro, Yarden Yavne, Daniel Shepshelovich
Leukemia & Lymphoma|May 26, 2020
Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administrationIrina Amitai, Pia Raanani, Daniel Shepshelovich
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 28, 2020
Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant BacteriaDafna Yahav, Noam Tau, Daniel Shepshelovich
Annals of Internal Medicine|July 28, 2020
Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort StudyNoam Tau, Dafna Yahav, Daniel Shepshelovich
Infectious Diseases and Therapy|February 17, 2021
Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the GapDafna Yahav, Daniel Shepshelovich, Noam Tau
Pageof 10